OTC Markets Group Earnings Call Transcripts
Fiscal Year 2025
-
Record 2025 results with 13% revenue growth, margin expansion, and strong gains across all segments. Strategic initiatives in overnight trading and OTCID drove new business, while capital returns to shareholders increased. Priorities for 2026 include scaling digital and international offerings.
-
Q3 2025 saw 15% revenue growth, strong performance across all business lines, and successful launches of overnight trading and OTCID Basic Market. Operating profit margin expanded, cash flow improved, and special and quarterly dividends were declared.
-
Q2 2025 saw 11% revenue growth, strong gains across all business lines, and the launch of OTC ID Basic Market. Operating profit margin was 29.9%, with EPS up 7% and free cash flow doubling year-over-year. Dividend of $0.18 per share declared.
-
Q1 2025 saw 10% revenue growth, led by OTC Link and market data licensing, with strong price-driven gains and expanding overnight trading initiatives. Corporate services stabilized, and the new OTC ID Basic Market launches July 1. Dividend and buybacks continued.
Fiscal Year 2024
-
Record annual revenues surpassed $111 million, driven by OTC Link growth, while corporate services declined. Key 2025 initiatives include OTC Overnight trading and the OTCID market launch, with continued focus on operational efficiency and shareholder returns.
-
Gross and net revenues grew modestly year-over-year in Q3 2024, with strong OTC Link performance offsetting declines in market data and corporate services. New initiatives include the launch of OTC Overnight and the planned OTCID market, while special and quarterly dividends were declared.
-
Q2 2024 saw 1% revenue growth, led by OTC Link's 12% increase, while corporate services declined. Adjusted EBITDA and EPS each fell 1% year-over-year, and a $0.18 per share dividend was declared. Strategic focus remains on global trading, compliance, and new product launches.